CAJ | 학술논문

心力衰竭（心衰）是由于任何心脏结构或功能异常导致心室充盈或射血能力受损的一组复杂临床综合征，其发病率、病死率高。肾素-血管紧张素-醛固酮系统（RAAS）的长期激活在心衰发生发展的病理生理学机制中发挥着重要作用。血管紧张素转换酶抑制剂（ACEI）、血管紧张素受体拮抗剂（ARB）以及醛固酮受体拮抗剂（MRA）已经被大规模临床试验证实对心衰具有良好的治疗效果，在心衰药物治疗策略中处于重要地位。2014年8月30日在欧洲心脏病学会年会首次公布PARADIM-HF的研究结果显示，在患者已经使用了β受体阻滞剂和MRA基础之上， LCZ696使心血管病死亡风险降低了20%，慢性心衰患者因心衰而住院的次数减少了21%。LCZ696以其独特的双相作用模式，再次证实调节神经内分泌是治疗心衰的现代观念。LCZ696将带来传统心衰药物治疗的革新。心衰治疗将大跨步进入一个新时代。
심력쇠갈（심쇠）시유우임하심장결구혹공능이상도치심실충영혹사혈능력수손적일조복잡림상종합정，기발병솔、병사솔고。신소-혈관긴장소-철고동계통（RAAS）적장기격활재심쇠발생발전적병리생이학궤제중발휘착중요작용。혈관긴장소전환매억제제（ACEI）、혈관긴장소수체길항제（ARB）이급철고동수체길항제（MRA）이경피대규모림상시험증실대심쇠구유량호적치료효과，재심쇠약물치료책략중처우중요지위。2014년8월30일재구주심장병학회년회수차공포PARADIM-HF적연구결과현시，재환자이경사용료β수체조체제화MRA기출지상， LCZ696사심혈관병사망풍험강저료20%，만성심쇠환자인심쇠이주원적차수감소료21%。LCZ696이기독특적쌍상작용모식，재차증실조절신경내분비시치료심쇠적현대관념。LCZ696장대래전통심쇠약물치료적혁신。심쇠치료장대과보진입일개신시대。
Heart failure (HF) is a complex clinical syndrome, which is caused by cardiac structural abnormalities and dysfunction. It can lead to ventricular filling and impaired ejection capacity with high incidence and mortality . The constant activation of the rennin-angiotensin-aldosterone system (RAAS) plays an important role in the development of heart failure. Angiotensin angiotensin converting enzyme inhibitor (ACEI), angiotensin angiotensin receptor antagonist (ARB) and aldoste?rone receptor antagonist (MRA) had been confirmed to be with good therapeutic effects therefore played important roles in heart failure treatment strategy shown by large scale clinical trials. The first PARADIM-HF data published by European So?ciety of Cardiology in annual meeting on August 30, 2014 showed that LCZ696 can reduce cardiovascular mortality risk of HF patient by 20%when combining with beta blockers and MRA . It also reduced the number of hospitalizations of patients with chronic heart failure (CHF) by 21%. LCZ696, using its unique dual phase mode verified that the regulation of neuroen?docrine is the modern concept for the treatment of heart failure. LCZ696 lead to innovation and shed new light in traditional drug treatment for heart failure.